Abl (Y253F), active

N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Y253F mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Y253F mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).

Catalog No. Size Price Quantity
14-759M 250 µg $2466.85
14-759 10 µg $305.91

For account specific pricing, please contact Customer Service at customerservicedrx@eurofins.com.

Related Family Members:

Target
Abl
Expression System
Expressed by baculovirus in Sf21 insect cells
Application
Kinase Assay
Molecular Weight
121kDa
Accession Number
U07563
Species
Human
Tag
6His
Purification Method
Ni2+/NTA-agarose
Content
Protein in 50mM Tris/HCl pH7.5, 150mM NaCl, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution.
Storage
6 months at -70°C
Bulk Sizes
Inquire